Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study.
Lamarca, Angela McCallum, Lynne Nuttall, Christina Barriuso, Jorge Backen, Alison C Frizziero, Melissa Leon, Rebecca Mansoor, Was McNamara, Mairéad G Hubner, Richard A
Lamarca, Angela
McCallum, Lynne
Nuttall, Christina
Barriuso, Jorge
Backen, Alison C
Frizziero, Melissa
Leon, Rebecca
Mansoor, Was
McNamara, Mairéad G
Hubner, Richard A
Citations
Altmetric:
Abstract
Patients with advanced well-differentiated neuroendocrine tumours (Wd-NETs) are commonly treated with somatostatin analogues (SSAs). Some patients may develop SSA-related side effects such as pancreatic exocrine insufficiency (PEI).
Description
Date
2018-07
Publisher
Collections
Keywords
Type
Article
Citation
Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. 2018, 12(7): 723-731 Expert Rev Gastroenterol Hepatol